Alcidion Group Reports Strong H1 FY25 Results and Secures Major Contracts

Alcidion Group Limited ( (AU:ALC) ) has issued an update.

Alcidion Group Limited reported a revenue of $17.6 million for the first half of FY25, with a significant improvement in underlying EBITDA to $0.5 million. The company has secured over $60 million in new sales year-to-date, including significant contracts in Australia and a milestone contract in the UK with North Cumbria Integrated Care Trust. These developments are expected to positively impact the company’s annual recurring revenue and position it for sustainable growth. Alcidion’s strategic focus on enhancing hospital efficiency through its Miya Precision platform is gaining traction, evidenced by new contracts and market entries, which are anticipated to bolster the company’s financial performance and shareholder value.

More about Alcidion Group Limited

Alcidion Group Limited operates in the healthcare technology industry, providing digital health solutions that focus on improving patient flow and hospital efficiency. Their primary product, Miya Precision, is a modular platform used for electronic patient records and clinical communications, with a market focus on Australia and recent expansions into the UK, including Wales.

YTD Price Performance: 53.33%

Average Trading Volume: 1,479,364

Technical Sentiment Consensus Rating: Sell

Current Market Cap: A$123.6M

For a thorough assessment of ALC stock, go to TipRanks’ Stock Analysis page.